Ocean Biomediacal, Inc. · OTC:OCEA
Ocean Biomediacal — Aesther Healthcare Acquisition — SPAC Merger (November 2022)
37 slides from Ocean Biomediacal's SPAC merger presentation, Nov 4, 2022
Slide 1: Ocean Biomedical Company Overview
Ocean Biomedical Company Overview _ + November 2022 Empowering Great Science. Accelerating Tr
Slide 2: Disclaimer
This presentation, prepared by Ocean Biomedical, Inc. ‘Ocean’ or the “Company”, is solely for informational purposes and is strictly confidential. The forwarding of such information to third parties is prohibited unless Ocean Biomedical has granted express permission to do so, ‘This presentation con
Slide 3: About Aesther Healthcare Acquisition Corp.
About Aesther Healthcare Acqu About Aesther Healthcare Acqu' n Corp. Purpose Aesther Healthcare is a serial special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with
Slide 4: Transaction Overview
Transaction Overview Key Transaction Highlights + Aesther Healthcare Acquisition Corp. ("AEHA") has agreed to acquire Ocean Biomedical, Inc. ("OCEA") at a purchase price of approximately $240M + The proposed transaction structure includes access to backstops totaling up to approximately $77M. + AEHA
Slide 5: Investment highlights: bench-to-bedside business model
Innovative business model bridges the ‘bench-to-bedside’ gap by accelerating the commercialization of innovative assets contained within research universities and medical centers Initial core portfolio in oncology, fibrosis, and infectious disease, all based on new target discoveries enabling first-
Slide 6: Management team and founders
Elizabeth Ng CEO, Director Proven biotechnology strategic leader Bioelectric Devices, BioMarin Pharmaceutical, Merck & Co, Gilead Sciences, Strategic Decisions Group, MBA Stanford, BS Massachusetts Institute of Technology BIOMARIN © MERCK (J GILEAD Dr. Jack A. Elias Co-Founder, Chair of SAB Dean of
Slide 7: Board of directors
a 4 9, OCEAN Martin Angle Deputy Chairman and Senior Independent Diector of ‘Spire Healthcare and Gul Keystone Petiolum, Executive carseat SG, Warburg & Co, Morgan Stanley, Dresdner Kieinwor, Group ple, Tera Firma Captal Parnes Se, University of Warwick Dr. Michelle Berrey President RAD and CMO, Int
Slide 8: Companies in one with continual growth
Ocean Biomedical is not 1 company but rather 3 companies in one - plus our business model ensures continual growth — Competitive Current Indications Advantages* & Drug Candidates* Growth Potential* Additional lung cancer + NSLC- mAb indications plus other + Novel biological targets ° NSLC- bi-specif
Slide 9: Bridging the bench-to-bedside gap
Bench Bedside (Lab) IND Enablement Clinical Development FDA Approval Commercial Launch (Market) 26,000/year invention disclosures* Patients with unmet medical needs $71B/year research expenditures* Pharma companies with dry pipelines Few cross the gap and reach the market * Driven by the goal of get
Slide 10: Business model and strategy designed to benefit patients
Our business model and strategy are designed to benefit patients and efficiently create value for our stakeholders and partners Access to innovatic hae OCEAN BIOMEDICAL et tin universities and 5 pathways... medical centers... Parent Operating Company (to be publicly listed - NASDAQ:OCEA) Portfolio o
Slide 11: Partner of choice for universities and medical centers
Approach: designed to make Ocean the ‘partner of choice’ for universities, medical centers and their researchers Typical Options for Institutions/ Researchers License . to pharma J a Z KD Launch gE a startup 7 Incubate / Coll Accelerate OCEAN BIOMEDICAL Challenges Pharma prefers later-stage assets E
Slide 12: Initial portfolio addresses high-value indications
Ocean’s initial portfolio addresses high-value and high-impact indications Our main programs in oncology, fibrosis, and infectious diseases are all nearing IND application, are licensed from Brown University and RI Hospital, and have been developed through past and on-going grants totaling $123.9M.
Slide 13: Current pipeline presents multiple shots on goal
Ocean’s current pipeline presents multiple ‘shots on goal’ Pipeline leverages research university/medical center partnerships to bring diverse and innovative candidates through preclinical studies IND Filing | PreIND inp ening aon Indication IND Filed Phase 1 Phase 2 Phase 3 a ocxas mtb chat wscie o
Slide 14: Core expertise and external resources
Ocean has core ex es and leverages external reso! OCEAN BIOMEDICAL Core operating team skilled at selecting assets and driving them through development + ies & capacity to accelerate development of multiple programs ws External capabi Drug Development Advisors Execution Advisory Services CROs / CMOs
Slide 15: Criteria-driven process to select new programs
We use a disciplined criteria-driven process to identify, assess and select new programs and indications - and to continually review existing ones Science Scientific Rationale / Model Predictability: + Does it make scientific sense? Unmet Need: + Will it profoundly benefit patients? Cross-functional
Slide 16: Comparators with programs in similar fields
a , Comparators With Programs Ocean Biomedical Portfolio in Sitnilar Field Oncology - NSCLC and GBM Kinnate Biopharma y (focused on specific kinase gene mutations) Plus: additional bispecific mAbs with immune SERAMPAN RO = eels checkpoint inhibitors & extension to other cancers 10/04/22 Market Cap:
Slide 17: Valuation attractive vs. peer group
Ocean’s valuation is extremely attractive vs. our peer group, particularly considering that Ocean is the parent company of 3 biotech companies $2,850 Valuations of peer group companies at closing on Tuesday 10/04/2022 (in millions)* $1,150" $1,060 $535 $534 $436 $396 g3g2 $336 $325 $228 $130 $128 S1
Slide 18: M&A transactions in IPF and oncology
M&A transactions in IPF and oncology highlight Ocean’s potential for exceptional value creation *Now in the market as Roche's Esbriet - (at Transaction) Transaction Impl Cee ie gece = " R IPF drug is Boehringer Ingelheim’ we Roche - Intermune, 2014” Phil $8.38 i Ie creaicbootinge BSI Biogen = 7 Biog
Slide 19: Positioned to deliver outsized value
ioned to deliver outsized * Our valuation is extremely attractive compared to our peer group - especially considering that Ocean is the parent company of 3 biotech companies (oncology, fibrosis, infectious diseases). * Ocean Biomedical does not have legacy preferred shareholders who often over-infla
Slide 20: Success of similar portfolio R&D approaches
The success of similar ‘portfolio R&D’ approaches supports the potential of Ocean's business model* Comparable Example Approacht Ocean Business Model Differentiation + Founded 2015 _ we + Focused primarily on single-gene rare diseases Brides bio + "Creates a bridge from remarkable advancements in ge
Slide 21: Sustainable growth strategy
Sustainable growth strategy is opportunistic with regards to indications, diseases, and therapeutic areas New programs Peeipaee - Additional indications, diseases, and therapeutic areas DOMICCGm - Selective process with stringent criteria that allows identification of with researchers / valuable ass
Slide 22: Oncology (NSCLC, GBM)
Oncology (NSCLC, GBM)
Slide 23: NSCLC and GBM have significant unmet needs
Non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM) have significant unmet needs Non-small cell lung cancer (NSCLC) Leading cause of cancer death and second most diagnosed cancer in the US + Affects approximately 460,000 people in the U.S. + Accounts for about 85% of new lung cancer
Slide 24: Science: Ocean's Innovation (Chi3L1)
Science Ocean’s Innovation jase 3-like-1 (Chi3L1) Novel target & pathway discovery: + Dysregulated and plays a critical role in the pathogenesis of primary and metastatic lung + Plays a synergistic effect with checkpoint inhibitors such as PD1 Neutralizing antibodies against Chi3L1 have been develop
Slide 25: Key takeaways about mAb candidates in oncology
Key takeaways about our humanized monoclonal antibody (mAb) therapeutic candidates in oncology Scientifically Compelling + Novel target: chi3I1 is a master regulator of many visceral tumors regardless of genetic mutations * First-in-class: proprietary mono-specific and bispecific mAbs are first to t
Slide 26: Fibrosis (IPF, HPS)
Fibrosis (IPF, HPS)
Slide 27: Fibrosis affects most organs and tissues
ibrosis affects most organs and tissues and is a leading cause of morbidity and mortality en oeeecoan ne ane: IPE Hermansky-Pudlak Syndrome Li . Idiopathic portal HTN ‘Autoi he coro. ung Liver (ooo Sees Dla pinay clea ee Se eaen ooe ae 7, pases Dryeye Congestive heart failure yee . . Fase se Diabeti
Slide 28: IPF and HPS have significant unmet needs
Idiopathic pulmonary fibrosis (IPF) & Hermanksy-Pudlak Syndrome (HPS) ificant unmet needs Idiopathic pulmonary fibrosis (IPF) Progressive disease that results in irreversible loss of lung function with high morbidity and mortality rates + IPF prevalence in the US has been reported to range from 10 t
Slide 29: Science: Ocean's Innovation (Chit1, OCF-203)
Science Ocean's Innovation OCF-203 has been inase 1 (Chit1) OCF-203 (Small Molecule X, or i ‘ Novel target & pathway discovery: SMX) was identified via high See in muleple Key regulator of tissue damage and remodeling. throughput screening as a ee ec urna + Critical biomarker and therapeutic target
Slide 30: Key takeaways about small molecule candidate in fibrosis
Key takeaways about our small molecule therapeutic candidate in fibrosis Scientifically Compelling + Novel target: chit1 is key regulator of tissue damage and remodeling + Potential for disease-modifying activity: 85-90% reduction in collagen accumulation in 4 pulmonary fibrosis animal models + Well
Slide 31: Infectious Diseases (Malaria)
Slide 32: Malaria: massive unmet public health need
~3 billion At risk of infection annually worldwide 200-300 million Infected annually worldwide 500,000+ Children under age 5 killed annually OCEAN The Need: Massive unmet public health need with no effective prophylactic vaccine Despite the recent hype and a $18 grant from Gates, Mosquirix has serio
Slide 33: Discovery of PfSEA-1 and PfGARP enables new strategy
The discovery of PfSEA-1 and PfGARP enables a promising new strategy for combating malaria which kills 500,000 children per year Science Malaria - Life-threatening disease Plasmodium falciparum] Caused by parasites and transmitted through the bites of infected female Anopheles mosquitoes Five parasi
Slide 34: Drug discovery platform yields malaria candidates
Proprietary drug discovery platform for infectious diseases has yielded promising vaccine and therapeutic candidates for malaria Activating PfGARP Triggers “Killer Switch" Recombinant protein immuni human primates with PFGARF © NoSerum = Pre-immune *49 Control (n=5) PIGARP is a protein expressed on
Slide 35: Key takeaways about malaria vaccine and therapeutics
Key takeaways about our vaccine and therapeutic candidates for malaria - and about our infectious disease target discovery platform PEGARP and PISEA-1 are critical for parasite survival * Proof of Concept: 100% killing of malaria parasites in in-vitro assays; >90% killing of malaria parasites in mRN
Slide 36: Executive Summary
Executive Summary Accessing innovations, developing them into high-value, clinical assets, and unleashing their value + Advantaged access to university & medical center inventions - maxi economic upside & involvement + ‘Drinking from a fire hose’ opportunity pipeline - continuously fuels Ocean's por
Slide 37: Thank you
Aesther Healthcare Acquisition — SPAC Merger (November 2022) on 6ix